AKR1C3 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to constitutively disrupt the AKR1C3 gene in the Jurkat T lymphoblastoid host background. This gene-edited cell model provides a loss-of-function platform for investigating AKR1C3-dependent steroid and prostaglandin metabolism in T-cell leukemia and immunological signaling contexts. The polyclonal format preserves a heterogeneous knockout population, enabling robust assessment of AKR1C3 function without the influence of clonal artifacts. Through CRISPR/Cas9-mediated gene disruption, these cells facilitate targeted studies of AKR1C3-mediated metabolic pathways and their roles in cellular proliferation, apoptosis, and drug response.
The Jurkat host cell line is an immortalized T lymphoblastoid cell line derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Jurkat cells are widely used as a model system for T-cell receptor (TCR) signaling, immunological synapse formation, and leukemogenesis. Their characteristic suspension growth and well-defined signaling cascades make them particularly suitable for dissecting pathways relevant to T-cell leukemia and immune cell function. The AKR1C3 knockout derivative retains the core Jurkat phenotype while allowing direct interrogation of gene-specific contributions to hormone and prostaglandin metabolism.
AKR1C3 encodes an aldo-keto reductase that catalyzes the NADPH-dependent reduction of 17-ketosteroids to active 17??-hydroxysteroids, including the conversion of androstenedione to testosterone and estrone to estradiol, thereby promoting androgen and estrogen receptor signaling. This enzyme also reduces prostaglandin D2 to 9??,11??-prostaglandin F2, modulating prostaglandin receptor-mediated pathways. AKR1C3 expression is transcriptionally regulated by the androgen receptor, estrogen receptor, Nrf2, IL-6/STAT3 signaling, and hypoxia-inducible factor HIF-1??. It functions within a broader steroidogenic network that includes HSD17B1, HSD17B3, SRD5A1, and CYP19A1, and its activity directly influences the levels of downstream effectors such as testosterone, estradiol, and prostaglandin metabolites.
In the Jurkat T-cell leukemia context, AKR1C3 knockout provides a powerful model for exploring the intersection of steroid metabolism and immune cell biology. Because Jurkat cells express functional TCR and downstream signaling machinery, the knockout enables dissection of how local androgen or estrogen production may influence T-cell activation, proliferation, or apoptosis. Moreover, aberrant AKR1C3 activity has been implicated in chemoresistance across multiple cancer types, making this model relevant for studying how altered hormone metabolism contributes to drug insensitivity in T-cell malignancies. The polyclonal population also allows assessment of heterogeneous responses to hormonal stimuli and therapeutic interventions.
These polyclonal knockout cells are engineered for a wide range of experimental applications, including investigation of AKR1C3 function in T-cell leukemia pathogenesis, characterization of steroid biosynthesis within immune cells, and evaluation of AKR1C3 as a therapeutic target. Standard validation assays include real-time qPCR and Western blotting to assess AKR1C3 knockdown efficiency. Functional studies can incorporate apoptosis assays (Annexin V/PI staining), cell viability measurements (MTT assay), and drug sensitivity profiling. Hormone metabolism can be monitored by LC-MS quantification of testosterone and estradiol, while prostaglandin pathway alterations can be assessed via metabolite assays. Additionally, flow cytometry enables analysis of receptor expression changes. For detailed protocols and further technical information, please contact Ascent Research.
